The pharmacological actions of Danzhi-xiaoyao-San on depression involve lysophosphatidic acid and microbiota-gut-brain axis: novel insights from a systems pharmacology analysis of a double-blind, randomized, placebo-controlled clinical trial

AbstractDanzhi-xiaoyao-San (DZXYS), a Traditional Chinese Medicine, plays an essential role in the clinical treatment of depression, but its mechanisms in humans remain unclear. To investigate its pharmacological effects and mechanisms as an add-on therapy for depression, we conducted a double-blind, placebo-controlled trial with depressed patients receiving selective serotonin reuptake inhibitors (SSRIs). Serum and fecal samples were collected for metabolomic and microbiome analysis using UHPLC-QTRAP-MS/MS and 16S rRNA gene sequencing technologies, respectively. Depression symptoms were assessed using the 24-item Hamilton Depression Scale. We employed network pharmacology, metabolomics, and molecular docking to identify potential targets associated with DZXYS. We also examined the correlation between gut microbes and metabolites to understand how DZXYS affects the microbiota-gut-brain axis. The results showed that DZXYS combined with SSRIs was more effective than SSRIs alone in improving depression. We identified 39 differential metabolites associated with DZXYS treatment and found seven upregulated metabolic pathways. The active ingredients quercetin and luteolin were docked to targets (AVPR2, EGFR, F2, and CDK6) associated with the enriched pathways 'pancreatic cancer' and 'phospholipase D signaling pathway', which included the metabolite lysophosphatidic acid [LPA(0:0/16:0)]. Additionally, we identified 32 differential gut microbiota species related to DZXYS treatment, with Bacteroides coprophilus and Ruminococcus gnavus showing negative correlations with specific metabolites such as L-2-aminobutyric acid and LPA(0:0/16:0). Our findings indicate that DZXYS's antidepressant mechanisms involve multiple targets, pathways, and the regulation of LPA and the microbiota-gut-brain axis. These insights from our systems pharmacology analysis contribute to a better understanding of DZXYS's potential pharmacological mechanisms in depression treatment.Communicated by Ramaswamy H. SarmaHIGHLIGHTSThis study presents a double-blind, randomized, placebo-controlled clinical trial comparing the clinical effects of Danzhi-xiaoyao-San (DZXYS) plus selective serotonin reuptake inhibitors (SSRIs) and SSRIs alone.This study is the first system pharmacology approach to integrate multi-omics and network pharmacology and examine the clinical pharmacological mechanisms of DZXYS as an add-on therapy for depression.This study highlights that regulation of lysophosphatidic acid (LPA) and the microbiota-gut-brain axis by DZXYS plays an essential role in its antidepressant mechanisms.Keywords: Danzhi-xiaoyao-Sandepressionlysophosphatidic acidmicrobiota-gut-brain axissystems pharmacologyclinical trialgut microbiotapharmacological mechanisms AcknowledgmentsWe thank International Science Editing (http://www.internationalscienceediting.com) for editing this manuscript.Disclosure statementThe authors declared there are no conflicts of interest for this study.Additional informationFundingThis work was supported by the National Natural Science Foundation of China (82004226, 81503475), China Postdoctoral Science Foundation (2020T130008ZX), Administration of Traditional Chinese and Tibetan Medicine of Qinghai Province (2016104), Natural Science Foundation of Guangdong Province (2021A1515011325, 2016A030313491), Science and Technology Plan Project of Guangdong Province (2019B030316001), Guangzhou municipal key discipline in medicine (2021–2023), and Guangzhou Municipal Science and Technology Project for Medicine and Healthcare (20201A011047, 20202A011016) Guangdong Provincial Hospital Association Pharmaceutical Research Special Foundation (2022YXKY11), Guangzhou Basic Research Program City-University (Institute) Joint Funding Project (SL2022A03J01499, 2023A03J0858).